Contineum Therapeutics, Inc. (CTNM)
8.37
+0.02
(+0.24%)
USD |
NASDAQ |
Oct 22, 10:14
Contineum Therapeutics Enterprise Value : 84.09M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 84.09M |
| October 20, 2026 | 88.23M |
| October 19, 2026 | 49.87M |
| October 16, 2026 | 36.33M |
| October 15, 2026 | 67.17M |
| October 14, 2026 | 76.20M |
| October 13, 2026 | 86.73M |
| October 12, 2026 | 92.18M |
| October 09, 2026 | 273.29M |
| October 08, 2026 | 265.77M |
| October 07, 2026 | 248.84M |
| October 06, 2026 | 245.83M |
| October 05, 2026 | 248.47M |
| October 02, 2026 | 263.51M |
| October 01, 2026 | 258.62M |
| September 30, 2026 | 274.79M |
| September 29, 2026 | 202.58M |
| September 28, 2026 | 248.84M |
| September 25, 2026 | 242.45M |
| September 24, 2026 | 239.81M |
| September 23, 2026 | 240.57M |
| September 22, 2026 | 274.04M |
| September 21, 2026 | 279.68M |
| September 18, 2026 | 278.93M |
| September 17, 2026 | 266.90M |
| Date | Value |
|---|---|
| September 16, 2026 | 287.58M |
| September 15, 2026 | 289.84M |
| September 14, 2026 | 327.45M |
| September 11, 2026 | 327.45M |
| September 10, 2026 | 321.44M |
| September 09, 2026 | 339.49M |
| September 08, 2026 | 369.58M |
| September 04, 2026 | 398.17M |
| September 03, 2026 | 430.89M |
| September 02, 2026 | 418.48M |
| September 01, 2026 | 392.52M |
| August 31, 2026 | 380.86M |
| August 28, 2026 | 411.33M |
| August 27, 2026 | 418.85M |
| August 26, 2026 | 410.20M |
| August 25, 2026 | 411.33M |
| August 24, 2026 | 395.53M |
| August 21, 2026 | 416.60M |
| August 20, 2026 | 372.59M |
| August 19, 2026 | 372.59M |
| August 18, 2026 | 315.42M |
| August 17, 2026 | 316.55M |
| August 14, 2026 | 303.76M |
| August 13, 2026 | 345.51M |
| August 12, 2026 | 333.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.11M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -66.36M |
| Fulcrum Therapeutics, Inc. | -31.31M |
| Definium Therapeutics, Inc. | 3.721B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.15M |
| Total Expenses (Quarterly) | 15.15M |
| EPS Diluted (Quarterly) | -0.4044 |
| Earnings Yield | -20.76% |
| Normalized Earnings Yield | -20.76 |